Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

Lignende værker

• Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib
  af: CHEN, YUH-MIN, et al.
  Udgivet: (2011)
• Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung
  af: HUANG, CHU-YUN, et al.
  Udgivet: (2014)
• Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
  af: Tseng, Jeng-Sen, et al.
  Udgivet: (2014)
• Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients
  af: Tseng, Yen-Han, et al.
  Udgivet: (2015)
• Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
  af: Costa, Daniel B., et al.
  Udgivet: (2008)